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Blood pressureInjections of noradrenaline into the lateral parabrachial nucleus (LPBN) increase arterial pressure and 1.8% NaCl
intake and decrease water intake in rats treated with the diuretic furosemide (FURO) combined with a low dose
of the angiotensin converting enzyme inhibitor captopril (CAP). In the present study, we investigated the inﬂu-
ence of the pressor response elicited by noradrenaline injected into the LPBN on FURO + CAP-inducedwater and
1.8% NaCl intake. Male Holtzman rats with bilateral stainless steel guide-cannulas implanted into LPBN were
used. Bilateral injections of noradrenaline (40 nmol/0.2 μl) into the LPBN increased FURO + CAP-induced 1.8%
NaCl intake (12.2 ± 3.5, vs., saline: 4.2 ± 0.8 ml/180 min), reduced water intake and strongly increased arterial
pressure (50 ± 7, vs. saline: 1 ± 1 mm Hg). The blockade of theα1 adrenoceptorswith the prazosin injected in-
traperitoneally abolished the pressor response and increased 1.8% NaCl and water intake in rats treated with
FURO + CAP combinedwith noradrenaline injected into the LPBN. The deactivation of baro and perhaps volume
receptors due to the cardiovascular effects of prazosin is amechanism thatmay facilitatewater andNaCl intake in
rats treated with FURO + CAP combined with noradrenaline injected into the LPBN. Therefore, the activation of
α2 adrenoceptors with noradrenaline injected into the LPBN, at least in dose tested, may not completely remove
the inhibitory signals produced by the activation of the cardiovascular receptors, particularly the signals that
result from the extra activation of these receptors with the increase of arterial pressure.
© 2013 Elsevier Inc. All rights reserved.1. Introduction
The lateral parabrachial nucleus (LPBN) is a major site that receives
ascending projections from the area postrema and the medial portion
of the nucleus of the solitary tract (AP/mNTS), an important area of
the hindbrain innervated by afferents from arterial baroreceptors,
cardiopulmonary receptors, gustatory receptors and other visceral
receptors that inﬂuence water and NaCl intake (Herbert et al., 1990;
Lança and van der Kooy, 1985; Johnson, 2007; Johnson and Thunhorst,
1997, 2007; Norgren, 1981).G II, angiotensin II; ANOVA, anal-
-dimetoxy-4-iodoamphetamine
-HT, serotonin; i.c.v., intra-
teral parabrachial nucleus;
y tract; NOR, noradrenaline;
subcutaneous; SCP, superior
gy and Pathology, School of
aitá, 1680, Araraquara, 14801
1 6488.
ghts reserved.The blockade of serotonin, cholecystokinin (CCK), corticotro-
phin releasing factor (CRF) or glutamate receptors, or activation of
α2-adrenoceptors in the LPBN increases hypertonic NaCl intake
and occasionally also water intake produced by the treatment
with the diuretic furosemide (FURO) combined with a low dose
of the angiotensin-converting enzyme inhibitor captopril (CAP),
both injected subcutaneously (s.c.), suggesting the existence of
important inhibitory mechanisms for the control of sodium and water
intake in the LPBN (Menani et al., 1996; Menani and Johnson, 1998;
De Gobbi et al., 2001; Andrade et al., 2004; De Castro e Silva et al.,
2006; De Gobbi et al., 2009; Gasparini et al., 2009).
The inﬂation of a balloon placed at the superior vena cava-right atrial
junction reduces 1.8% NaCl intake induced by FURO + CAP treatment
and increases c-fos protein in the LPBN, suggesting that the LPBN
might be a site that receives signals from cardiovascular receptors
that inhibit sodium intake (De Gobbi et al., 2008). The changes in the
activities of these cardiovascular receptors caused by reductions or
increases in the arterial pressure might facilitate or inhibit, respec-
tively, water and sodium intake (Thunhorst and Johnson, 1994;
Johnson and Thunhorst, 1997, 2007; Johnson, 2007; De Gobbi
et al., 2008). However, the injections of noradrenaline into the
LPBN facilitate FURO + CAP-induced sodium intake, in spite of the
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(Gasparini et al., 2009).
The facilitation of FURO + CAP-induced 1.8% NaCl intake produced
by the injections of noradrenaline into the LPBN similar to the facilita-
tion produced by moxonidine (α2-adrenoceptor and imidazoline ago-
nist) into the LPBN depends on the activation of the α2-adrenoceptors
in the LPBN (Andrade et al., 2004; Gasparini et al., 2009). The only differ-
ence is that the activation of theα2-adrenoceptorswith the injections of
moxonidine into the LPBN does not modify arterial pressure (Andrade
et al., 2004). This may explain why noradrenaline is less effective than
moxonidine injected into the LPBN to increase FURO + CAP-induced
sodium intake and also differently from moxonidine, noradrenaline
reduces FURO + CAP-induced water intake.
In the present study, we investigated the inﬂuence of the pressor
response produced by noradrenaline on water and 1.8% NaCl intake
by rats treated with s.c. FURO + CAP and the possible peripheral
mechanisms (sympathetic activation and/or vasopressin secretion)
that might be activated by the injections of noradrenaline injected
into the LPBN to produce pressor responses. For this, we tested the
effects of the blockade of the pressor response to noradrenaline injected
into the LPBN with intraperitoneal (i.p.) injection of prazosin (speciﬁc
α1 adrenoceptor antagonist) on FURO + CAP-induced water and 1.8%
NaCl intake and the effects of the intravenous (i.v.) injection of a vaso-
pressin antagonist combinedwith hexamethonium (ganglionic blocker)
on the pressor and bradycardic responses to noradrenaline injected into
the LPBN in unanesthetized rats. Additionally, we also evaluated the
cardiovascular and sympathetic responses to noradrenaline injected
into the LPBN in anesthetized rats.2. Material and methods
2.1. Animals
Male Holtzman rats (for tests in unanesthetized animals) or Wistar
rats (for tests in anesthetized animals) weighing 280 to 320 g were
used. The animals were housed individually in stainless steel cages
in a room with controlled temperature (23 ± 2 °C) and humidity
(55 ± 10%). The lights were on from 7:00 am to 7:00 pm. Guabi rat
chow (Paulínia, SP, Brazil), tap water and 1.8% NaCl were available ad
libitum. Animals' use was in accordance with the guidelines approved
by the Animal Experimentation Ethics Committee of the Dentistry
School of Araraquara — UNESP and Institute of Biomedical Science at
theUniversity of São Paulo (ICB/USP). All effortsweremade tominimize
animal discomfort and the number of animals used.2.2. Brain surgery
The animals were anesthetized with ketamine (80 mg/kg of body
weight i.p.) and xylazine (7 mg/kg of body weight i.p.) and placed in
a Kopf stereotaxic instrument. The skull was positioned to have
the bregma and lambda at the same horizontal level. Stainless steel
cannulas (12 × 0.6 mm o.d.) were implanted bilaterally in the LPBN
(coordinates: 9.4 mm caudal to bregma, 2.1 mm lateral to midline and
4.1 mmbelow theduramater). The tips of the cannulaswere positioned
at a point 2 mm above the LPBN. Besides the LPBN cannulas, one group
of rats, received also stainless steel cannulas implanted into the lateral
ventricle (LV, coordinates: 0.3 mm caudal to bregma, 1.5 mm lateral
to midline and 3.5 mm below the dura mater). The cannulas were
ﬁxed to the cranium using dental acrylic resin and jeweler screws. At
the end of the surgery, the animals received an intramuscular injection
of penicillin (30,000 IU) and an s.c. injection of the analgesic Ketoﬂex
(ketoprofen 1%, 0.03 ml/rat).
After the surgery, rats were allowed to recover for one week before
starting water and NaCl intake tests or arterial pressure recordings.2.3. Arterial pressure and heart rate recordings in unanesthetized animals
The mean arterial pressure and HR were recorded in unan-
esthetized rats. Under ketamine anesthesia (100 mg/kg of body
weight i.p.) and xylazine (7 mg/kg of body weight i.p.), a polyeth-
ylene tubing (PE-10 connected to a PE-50) was inserted into the
abdominal aorta through the femoral artery on the day before the
experiments. At the same time, in some rats, a polyethylene tubing
was also inserted in the femoral vein for drug administration. Both
tubings were tunneled subcutaneously and exposed on the back
of the rat to allow access in unrestrained, freely moving rats. To
record pulsatile arterial pressure (PAP), MAP and HR, the arterial
catheter was connected to a Statham Gold (P23 Db) pressure
transducer connected with an ETH-200 ampliﬁer (CB Sciences)
and to a PowerLab data acquisition systems (ADInstruments).2.4. Sympathetic nerve activity recording
The rats were deeply anesthetized with halothane (5% in 100%
oxygen in inspired air) for general surgical procedures, such as:
a) tracheostomy for artiﬁcial ventilation; b) femoral artery and
vein catheterization for arterial pressure measurement and admin-
istration of ﬂuids and drugs, respectively; c) intracerebral injection
by removal of the occipital bone and retracting the underlying dura
mater membrane for insertion of a pipette into the medulla
oblongata via a dorsal transcerebellar approach; d) splanchnic
sympathetic nerve isolation for subsequent nerve activity monitor-
ing. The level of anesthesia was checked by a ﬂexor reﬂex to the
animal's paw pinching.
Splanchnic sympathetic nerve activity (sSNA)was recorded as previ-
ously described (Totola et al., 2013). Brieﬂy, the right splanchnic nerve
was isolated via a retroperitoneal approach, and the segment distal to
the suprarenal ganglion was placed on a pair of Teﬂon-coated silver
wires that had been bared at the tip (250 μm bare diameter; A-M
Systems, www.a-msystems.com). The nerves and wires were embed-
ded in adhesive material (Kwik-Cast Sealant, WPI, USP), and the
wound was closed around the exiting recording wires.
Upon completion of the surgical procedures, halothanewas replaced
by urethane (1.2 g/kg of body weight) slowly administered intrave-
nously (i.v.). All rats were artiﬁcially ventilated with 100% oxygen
throughout the experiment. The rectal temperature was maintained at
37 °C and the end tidal-CO2 wasmonitored throughout the experiment
with a capnometer (CWE, Inc., Ardmore, PA, USA) that was calibrated
twice per experiment against a calibrated CO2/N2 mix. The adequacy
of the anesthesia was monitored during a 20 minute stabilization peri-
od by testing for the absence of withdrawal response and the lack of
arterial pressure change to ﬁrm toe pinch. After these criteria were
satisﬁed, the muscle relaxant pancuronium was administered at the
initial dose of 1 mg/kg i.v. and the adequacy of anesthesia was thereaf-
ter gauged solely by the lack of increase in arterial pressure to ﬁrm toe
pinch. Approximately hourly supplements of one-third of the initial
dose of urethanewere needed to satisfy these criteria during the course
of the recording period (2–3 h).
As previously described (Wenker et al., 2013; Totola et al., 2013),
mean arterial pressure (MAP), sSNA and end-expiratory CO2 (etCO2)
were digitized with a micro1401 (Cambridge Electronic Design), stored
on a computer, and processed off-linewith version 6 of Spike 2 software
(Cambridge Electronic Design). Integrated splanchnic nerve activities
(∫SNA) were obtained after the rectiﬁcation and smoothing (τ = 2 s)
of the original signal, which was acquired with a 30–300 Hz bandpass
ﬁlter. ∫SNA was normalized within animals by assigning a value of
100 to resting SNA and a value of 0 to the minimum value recorded
either during the administration of a dose of phenylephrine that
saturated the baroreﬂex (5 μg/kg, i.v.) or after ganglionic blockade
(hexamethonium; 10 mg/kg, i.v.).
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All drugs were purchased from Sigma Chemical Co, St. Louis, MO,
USA. Noradrenaline (norepinephrine bitartrate, 10, 15, 20 or
40 nmol/0.2 μl), was injected into the LPBN to test the effects on
MAP and HR. Noradrenaline at the dose of 40 nmol/0.2 μl was
used on ingestive behavior tests.
Prazosin chloride (1 mg/kg of body weight) was injected i.p. Furose-
mide (10 mg/kg of bodyweight) and captopril (5 mg/kg of bodyweight)
were injected s.c. [β-Mercapto-β-, β-cyclopentamethylenepropionyl,
O-me-Tyr2, Arg8] vasopressin (Manning Compound, 10 mg/kg of
body weight), arginin vasopressin (12.5 ng/rat) and hexamethonium
chloride (30 mg/kg of body weight) were injected intravenously (i.v.).
Noradrenaline, prazosin, vasopressin, Manning Compound and
hexamethonium were dissolved in isotonic saline. The saline was
injected into LPBN as control treatment.
The doses of the drugs used were based on previous studies that
injected these drugs centrally or peripherally (Gasparini et al., 2009;
Menani et al., 2000; Menani and Johnson, 1998; Sugawara et al., 1999).2.6. Central injections
The injections into the LPBNweremade using 5 μl Hamilton syringes
connected by a polyethylene tubing (PE-10) to injector cannulas
(0.3 mm o.d.). The injector cannulas were 2 mm longer than the guide
cannulas. The volume of injection into the LPBN was 0.2 μl in each site
and into the LV 1 μl.2.7. Water and 1.8% NaCl intake tests
For the tests, water and 1.8% NaCl were provided from burettes
with 0.1 ml divisions that were ﬁtted with metal drinking spouts.
Water and 1.8% NaCl intake was induced by s.c. injections
of FURO (10 mg/kg of body weight) + CAP (5 mg/kg of body
weight). Immediately after the treatment with FURO + CAP, the
rats were maintained without water or 1.8% NaCl for 1 h. After
this period, water and 1.8% NaCl were offered to the animals and
the cumulative intake was recorded for 3 h.
Saline or noradrenalinewas injected into LPBN15 min before the an-
imals' access to water and 1.8% NaCl. When used, the α1-adrenoceptor
antagonist, prazosin or saline was injected i.p. 15 min before the injec-
tions of the agonists.
A recovery period of at least 2 days was allowed between tests.
During the tests rats had no access to food.2.8. Histology
At the end of the experiments, the animals received bilateral injec-
tions of 2% Evans blue solution (0.2 μl) into LPBN. Theywere then deep-
ly anesthetized with sodium thiopental (60 mg/kg of body weight) and
perfused transcardially with 10% formalin. The brains were removed
and ﬁxed in 10% formalin for at least 2 days. Then, the brains were fro-
zen, cut in 60 μm sections, stained with Giemsa and analyzed by light
microscopy to conﬁrm the central sites of the injections.2.9. Statistical analysis
The results were analyzed by two-way repeated measures ANOVA
(counterbalanced design tests) or two-way ANOVA with treatments
and times as factors or one way ANOVA. In all the cases, ANOVA was
followed by Newman–Keuls test. Differences were considered signiﬁ-
cant at p b 0.05.2.10. Experimental protocols
2.10.1. Water and 1.8% NaCl intake induced by FURO + CAP in rats treated
with prazosin i.p.
The rats with bilateral stainless steel guide-cannulas implanted into
LPBN were treated with FURO (10 mg/kg b. wt.) combined with CAP
(5 mg/kg b. wt.) s.c. Noradrenaline (40 nmol/0.2 μl) or salinewas bilat-
erally injected into the LPBN 45 min after FURO + CAP-treatment.
Prazosin (1 mg/kg of body weight) or saline was injected i.p. 15 min
before the injections of noradrenaline or saline into the LPBN. The mea-
surements of water and 1.8% NaCl intake started 15 min after the LPBN
injections and were made at every 30 minutes during 180 min.
To test the effects of noradrenaline into the LPBN combined with
prazosin i.p., the rats treated with FURO + CAP received the follow-
ing combination of treatments: saline i.p + saline into LPBN; saline
i.p. + noradrenaline into LPBN; prazosin i.p. + saline into LPBN;
prazosin i.p. + noradrenaline into LPBN. In each test, after the treat-
ment with FURO + CAP, the group of rats was divided in two and
half of the group received one of the treatments described above
and the remaining animals received another treatment into the
LPBN. The sequence of the treatments into LPBN and i.p. in each rat
in the different tests was randomized and at the end of the experi-
ments each rat received all the four treatments.
The interval between two tests was at least 48 h.
2.10.2. Cardiovascular responses to the injections of noradrenaline into the
LPBN combined with prazosin i.p. in unanesthetized rats
In order to conﬁrm that prazosin (1 mg/kg of body weight) i.p. was
also able to block the pressor responses to the same dose of noradrena-
line (40 nmol/0.2 μl) injected bilaterally into the LPBN in the behavior
tests, the rats treated with FURO (10 mg/kg b. wt.) combined with
CAP (5 mg/kg b. wt.) s.c. received bilateral injections of saline and
noradrenaline (40 nmol/0.2 μl) into the LPBN 40 and 45 min, respec-
tively, after FURO + CAP-treatment. Prazosin (1 mg/kg of bodyweight)
or saline was injected i.p. 15 min before the injections of noradrenaline
into the LPBN. MAP and HR were recorded for an additional 30 min
period after the injections of noradrenaline. MAP andHRwere recorded
in the same group of rats in two different sessions with a 24 h interval
between them. In one session the rats received an injection of prazosin
i.p. and in the other saline i.p. The order of the injection of saline or
prazosin i.p. in each session in different rats was randomized.
2.10.3. Cardiovascular responses to noradrenaline injected into the LPBN
in unanesthetized rats that received hexamethonium combined with
vasopressin receptor antagonist injected i.v.
In order to investigate the possible mechanisms involved in the
pressor response to noradrenaline injected into the LPBN we tested
the effects of the ganglionic blockade with i.v. hexamethonium com-
bined with the blockade of vasopressin receptors with i.v. injection of
Manning Compound.
Normotensive ﬂuid replete unanesthetized rats with stainless steel
guide-cannulas implanted in the LV and bilaterally in the LPBN and
with polyethylene tubing inserted into the abdominal aorta through
the femoral artery and into the femoral vein were used. After a period
of control recording of baseline MAP and HR (around 20 min), rats
received i.v. injections of vasopressin antagonist (Manning Compound,
10 μg/kg of body weight) or saline combined with i.v. injections of
hexamethonium (30 mg/kg of body weight) or saline. Ten and 15 min
later, the animals received unilateral injection of saline and noradrena-
line (20 nmol/0.2 μl) into LPBN, respectively. Fifteen minutes after the
injection of noradrenaline into the LPBN, the rats received i.c.v. injection
of carbachol (4 nmol/1 μl).MAP andHRwere recorded for an additional
15 min period after the injection of carbachol. MAP and HR were
recorded in two different sessions with a 24 h interval between them.
In one session the rats received injection of saline i.v. and in the other
the combination of vasopressin antagonist and hexamethonium i.v.
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different rats was randomized.
Before the i.v. injections of the vasopressin antagonist combined
with hexamethonium and after the injections of noradrenaline into
the LPBN, rats received i.v. injections of vasopressin (12.5 ng/rat) to
conﬁrm the vasopressinergic receptor blockade.
2.10.4. Cardiovascular and sympathetic responses produced by injection of
noradrenaline into the LPBN in anesthetized rats
These experiments were performed in rats anesthetized with
urethane (1.2 g/kg, i.v.). The recordings began 10 min after the connec-
tion of the arterial line to the pressure transducer. The mean arterial
pressure (MAP) and splanchnic sympathetic nerve activity (sSNA)
were continuously recorded for 70–80 min. The control (baseline)
values were recorded for 10–20 min and were analyzed immediately
before the vehicle injection (ﬁrst treatment). These values were used
as a reference to calculate the changes produced by the treatments.
After 10 min, noradrenaline (20 nmol/0.2 μl) was injected unilaterally
into the LPBN and the MAP and sSNA responses were evaluated imme-
diately. The same experimental protocol was repeated twice during the
experiment.
3. Results
3.1. Histological analysis
The LPBN injection siteswere centered in the central lateral or dorsal
lateral portions of the LPBN (see Fulwiler and Saper, 1984, for deﬁni-
tions of the LPBN subnuclei) (Fig. 1). The sites of the injections into
the LPBN in the present study were similar to those of previous studies
showing the effects of the injections of methysergide, moxonidine or
noradrenaline into the LPBN on NaCl and water intake (Menani et al.,
1996; Menani and Johnson, 1998; De Gobbi et al., 2001; Andrade
et al., 2004; De Gobbi et al., 2009; Gasparini et al., 2009).
The results from rats with injections outside the LPBN were also an-
alyzed. Fig. 1B to G illustrates the most common sites of injections out-
side the LPBN.
3.2. Water and 1.8% NaCl intake induced by FURO + CAP in rats treated
with noradrenaline into LPBN combined with prazosin i.p.
Bilateral injections of noradrenaline (40 nmol/0.2 μl) into the LPBN
increased FURO + CAP-induced 1.8% NaCl intake [F (3, 30) = 5.89;
p b 0.05] (Fig. 2A) and reduced water intake in the ﬁrst 90 min of the
test [F (3, 30) = 5.69; p b 0.05] (Fig. 2B). The injections of noradrena-
line into the LPBN combined with prazosin (1 mg/kg of body weight)
i.p. further increased FURO + CAP-induced 1.8% NaCl intake (Fig. 2A)
and, in addition, also increased water intake (Fig. 2B).
The injection of prazosin i.p. alone slightly increased water intake in
ﬂuid replete rats or in rats treatedwith FURO + CAP, without changing
1.8% NaCl intake (Fig. 2, Table 1). Prazosin i.p. combinedwith noradren-
aline injected into LPBN produced no change of 1.8% NaCl or water
intake by ﬂuid replete rats (Table 1).
3.3. Cardiovascular responses to the injections of noradrenaline into the
LPBN combined with prazosin i.p. in unanesthetized rats
The bilateral injections of noradrenaline (40 nmol/0.2 μl) into the
LPBN in rats treated with FURO + CAP s.c. increased MAP [F (3,
15) = 38.53; p b 0.05] and reduced HR [F (3, 15) = 9.38; p b 0.05]
(Fig. 3, Table 2). The i.p. injection of prazosin (1 mg/kg of body weight)
abolished the pressor and bradycardic responses to bilateral injections
of noradrenaline (40 nmol/0.2 μl) injected into the LPBN in rats treated
with FURO + CAP s.c. (Fig. 3, Table 2).
The i.p. injections of prazosin in FURO + CAP-treated rats produced
a long lasting reduction in MAP that reached the maximum of −34 ±3 mm Hg compared to saline i.p. (2 ± 3 mm Hg) [F (2, 19) = 58.14;
p b 0.05] and increased HR (101 ± 10 bpm, vs. saline i.p.: 20 ±
12 bpm) [F (2, 19) = 4.02; p b 0.05] (Fig. 3).
3.4. Cardiovascular responses to noradrenaline injected into the LPBN
in unanesthetized rats that received hexamethonium combined with
vasopressin receptor antagonist injected i.v.
To investigate the possible mechanisms involved in the pressor
response to noradrenaline injected into the LPBN we tested the effects
of the ganglionic blockade with i.v. hexamethonium combined with
the blockade of vasopressin receptors with i.v. injection of Manning
Compound.
The pressor response to noradrenaline (20 nmol/0.2 μl) injected
unilaterally into LPBN increased in rats pre-treated with the vaso-
pressinergic receptor antagonist (Manning Compound, 10 μg/kg of
body weight) combined with hexamethonium (30 mg/kg of body
weight) i.v. [F (3, 12) = 15.83; p b 0.05] (Fig. 4A). However, the
bradycardic response to noradrenaline injected into the LPBN was
abolished with this pre-treatment [F (3, 12) = 3.66; p b 0.05]
(Fig. 4B). In the same animals, the vasopressinergic antagonist com-
bined with hexamethonium i.v. abolished the pressor response to car-
bachol (4 nmol/1 μl) injected i.c.v. (Fig. 4A), conﬁrming the efﬁciency
of the combined sympathetic and vasopressinergic blockade.
The pressor response to i.v. vasopressin (12.5 ng/0.1 ml/rat) was
abolished by the i.v. injection of the vasopressinergic receptor antago-
nist (2 ± 4 mm Hg, vs. control pre-antagonist: 36 ± 3 mm Hg)
which also conﬁrms the efﬁciency of the blockade.
3.5. Cardiovascular and sympathetic responses produced by injection of
noradrenaline into the LPBN in anesthetized rats
In urethane-anesthetized rats (basalMAP: 122 ± 6 mm Hg, n = 5),
the unilateral injection of noradrenaline (20 nmol/0.2 μl) into the LPBN
increased MAP (30 ± 5, vs. saline: 4 ± 3 mm Hg, p b 0.05) and
decreased sSNA (−22 ± 8%, vs. saline: 4 ± 2%, p b 0.05). The injection
of the same dose of noradrenaline (20 nmol) intravenously also
increased MAP (44 ± 10, vs. saline: 1 ± 1 mm Hg, p b 0.01) and
reduced sSNA (−83 ± 2%, vs. saline: 1 ± 2%, p b 0.01).
3.6.Water and 1.8% NaCl intake induced by FURO + CAP and cardiovascu-
lar responses to noradrenaline injected outside the LPBN
To test the speciﬁcity of the LPBN as the site in which the injections
of noradrenaline produced effects on water and 1.8% NaCl intake and
arterial pressure, the responses noradrenaline injected outside the
LPBN were also analyzed.
Bilateral injections of noradrenaline (40 nmol/0.2 μl) in sites outside
the LPBN in unanesthetized rats also increased MAP (39 ± 4) and
decreased HR (−82 ± 15) similarly to the injection into the LPBN
(Table 3). Injections of noradrenaline (40 nmol/0.2 μl) in sites outside
the LPBN did not modify FURO + CAP-induced 1.8% NaCl intake
(Table 4).
4. Discussion
A previous study demonstrated that noradrenaline acting on α2
adrenoceptors in the LPBN facilitates sodium intake induced by
FURO + CAP treatment (Gasparini et al., 2009). The present results
conﬁrm this effect of noradrenaline injected into the LPBN and show
that the blockade of the α1 adrenoceptors with prazosin injected i.p.
abolished the pressor response to noradrenaline and increased 1.8%
NaCl compared to the intake after combining s.c. FURO + CAP with
noradrenaline into the LPBN. Water intake induced by FURO + CAP
was reduced by noradrenaline injected into the LPBN and increased by
combining noradrenaline into the LPBN with prazosin i.p. These results
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receptors due to the cardiovascular effects of prazosin is a possible
mechanism that facilitates water intake and increases the facilitation
of NaCl intake in rats treated with FURO + CAP combined with
noradrenaline injected into the LPBN.
Although prazosin i.p. abolished the pressor response to noradrena-
line injected into the LPBN, the ganglionic blockade with hexamethoni-
um combined with the blockade of peripheral vasopressin receptors
increased, rather than decreased, the pressor response to noradrenalineFig. 1.Photomicrographsof coronal sections of rat brains showing (A) the injection sites into the
cerebellar peduncle.injected into the LPBN. Additionally, experiments performed in anesthe-
tized rats showed that an injection of noradrenaline into the LPBN pro-
duced a pressor response and a decrease in sympathetic outﬂow, an
effect opposite to that expected for a central acting hypertensive
agent. Therefore, the results strongly suggest that the pressor response
results from noradrenaline acting peripherally and not centrally.
Afferent signals from arterial baroreceptors and cardiopulmonary
receptors that reach the AP/mNTS ascend to the LPBN and can inhibit
the ingestion of water and sodium (Johnson, 2007; Johnson andLPBNand (B, C,D, E, F andG) the injections in sites outside the LPBN(arrows). scp, superior
Table 1
Cumulative 1.8% NaCl and water intake by ﬂuid replete rats treated with bilateral
injections of noradrenaline or saline into LPBN combined with prazosin or saline i.p.
Treatments 1.8% NaCl intake
(ml/2 h)
Water intake
(ml/2 h)
SAL i.p. + SAL LPBN 0.6 ± 0.3 0.9 ± 0.6
SAL i.p. + NOR LPBN 0.3 ± 0.2 0.3 ± 0.2
Prazosin i.p. + SAL LPBN 0.7 ± 0.3 2.8 ± 0.6a
Prazosin i.p. + NOR LPBN 1.5 ± 0.9 2.2 ± 0.7
The results are reported as means ± SEM. Number of animals = 6. Noradrenaline (NOR,
40 nmol/0.2 μl); prazosin (1 mg/kg of body weight); saline (SAL).
a Different from SAL + SAL.
A
Time (min)
Cu
m
ul
at
iv
e 
w
at
er
 in
ta
ke
 (m
l)
0
5
10
15
20
*
*
*
*
*
#
#
#
#
#
# ##
#
B
Time (min) 
0 30 60 90 120 150 180
0 30 60 90 120 150 180
Cu
m
ul
at
iv
e 
1.
8%
 N
aC
l i
nt
ak
e 
(m
l)
0
5
10
15
20
SAL i.p. + SAL LPBN
SAL i.p. + NOR LPBN
PRAZOSIN i.p. + NOR LPBN
PRAZOSIN i.p. + SAL LPBN
 n = 11
*
* *
*
*
*
* different from SAL i.p. + SAL LPBN
#
# ##
# different from SAL i.p. + NOR LPBN
Fig. 2. Cumulative (A) 1.8% NaCl intake and (B) water intake induced by FURO + CAP in
rats treated with bilateral injections of noradrenaline (NOR, 40 nmol/0.2 μl) or saline
(SAL) into the LPBN combined with prazosin (1 mg/kg of body weight) or SAL i.p. The
results are reported as means ± SEM. n = number of animals.
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receive other visceral signals important to the control of sodium and
water intake, like signals from gustatory receptors or osmoreceptors
(Franchini and Vivas, 1999; Kobashi et al., 1993; Norgren, 1995;
Yamamoto et al. 1993). The inﬂation of a balloon placed at the superior
vena cava-right atrial junction reduces 1.8% NaCl intake produced by
FURO + CAP treatment and increases c-fos protein in the LPBN
(De Gobbi et al., 2008). The activation of the superior vena cava-right
atrial junction receptors also attenuates isoproterenol-induced water
intake in intact rats, and this inhibition is abolished by electrolytic
lesions of the LPBN (Ohman and Johnson, 1995). These results suggest
that the LPBN is a site that receives signals from cardiovascular recep-
tors that inhibit sodium and water intake. The present results show
that the pre-treatmentwith prazosin i.p. abolished the pressor response
and increased water and NaCl intake by rats treated with FURO + CAP
combined with noradrenaline injected into the LPBN. In addition to the
blockade of the pressor response to noradrenaline, prazosin i.p. also
reduced baseline arterial pressure and this might also reduce the inhibi-
tion produced by cardiovascular receptor activity. Therefore, by
blocking the pressor response to noradrenaline injected into the LPBN
and/or reducing the baseline arterial pressure, prazosin injected i.p.
causes the unloading of baroreceptors and possible volume receptors
which might facilitate water and NaCl intake. In this case, it seems
that inhibitory signals from cardiovascular receptors (those removed
by prazosin i.p.) still affect water and NaCl intake after the injections
of noradrenaline into the LPBN, which suggests that the activation of
α2 adrenoceptors with noradrenaline injected into the LPBN, at least
in the dose tested, may not completely remove the inhibitory signals
produced by the activation of the cardiovascular receptors, particularly
the signals that result from the extra activation of these receptors pro-
duced by the increase of arterial pressure. Studies that have investigated
the ingestion of 1.8% NaCl and water by FURO + CAP-treated rats
suggest that the small reduction of the arterial pressure (around
10 mm Hg) produced by this treatment is important to stimulate the
intake (Thunhorst and Johnson, 1994). Although the peak of the pressor
response to noradrenaline was transitory and occurred before the
intake, a long lasting small increase of arterial pressure is maintained
for at least 30 min (Δ = 12 ± 4 mm Hg at 30 min after noradrenaline
injection)which is the opposite to the effects of FURO + CAP-treatment,
and, therefore, might inhibit sodium and water intake.
The suggestion that the blockade of inhibitory signals by α2
adrenoceptor activation in LPBN facilitates FURO + CAP-induced
hypertonic NaCl intake is reinforced by the results of a previous study
that demonstrated that the activation of α2 adrenoceptors with the
injections of moxonidine (an α2 adrenoceptors/imidazoline receptor
agonist) into the LPBN reduces the aversive responses, and increases
the ingestive responses, to an intra-oral infusion of hypertonic NaCl in
rats (Andrade et al., 2011). A main difference between the injection of
noradrenaline and moxonidine into the LPBN is the absence of pressor
response when moxonidine is injected into the LPBN (Andrade et al.,
2004). The activation of LPBN α2 adrenoceptors by moxonidine injec-
tion without changes in arterial pressure produces an intense facilita-
tion of sodium intake probably as a consequence of the reduced
activation of inhibitory signals in this condition, differently from the
injection of noradrenaline into the LPBN that produces an extra activa-
tion of the inhibitory mechanisms due to the pressor responses.
Moxonidine injected into the LPBN in a small dose (0.5 nmol/0.2 μl)
strongly enhances FURO + CAP-induced 0.3 M NaCl intake (the mean
ingestion of rats reaches 40 ml in 2 h) (Andrade et al., 2004). Although
noradrenaline also activates α2 adrenoceptors in the LPBN, the inges-
tion of 0.3 M NaCl by rats treated with FURO + CAP combined with
noradrenaline injected into the LPBN is reduced compared to that of
rats treated with moxonidine into the LPBN. Rats treated with nor-
adrenaline into the LPBN only reach an ingestion of 0.3 M NaCl similar
to that of rats treated with moxonidine into the LPBN when they were
previously treated with prazosin i.p., which again reinforces thesuggestion that the inhibitory signals probably from cardiovascular ori-
gin are those that reduce the facilitation of sodium intake produced nor-
adrenaline injected into the LPBN. In addition to cardiovascular signals,
the LPBN also receives other inhibitory signals of sodium ingestion, like
osmoreceptor signals, that might be modiﬁed by the activation of α2
adrenoceptors in this area facilitating sodium intake (Andrade et al.,
2011). Moreover, besides α2 adrenergic mechanisms, other different
Time (min)
B
noradrenaline
(LPBN)
SAL
(LPBN)
prazosin
(i.p.)
A
SAL
(LPBN)
noradrenaline
(LPBN)
Time (min)
Fig. 3. Representative recordings showing the changes in PAP, MAP and HR in one rat treated with FURO + CAP s.c. that received bilateral injections of saline (SAL) or
noradrenaline (NOR, 40 nmol/0.2 ml) into LPBN combined with prazosin (1 mg/kg of body weight) i.p.
Table 2
Changes inMAP andHR produced by bilateral injections of noradrenaline (NOR, 40 nmol/
0.2 μl) or saline into LPBN combined with prazosin or saline i.p. in rats treated with
FURO + CAP.
Treatments ΔMAP
(mm Hg)
ΔHR
(bpm)
SAL i.p. + SAL LPBN 1 ± 1 1 ± 4
SAL i.p. + NOR LPBN 50 ± 7a −62 ± 13a
Prazosin i.p. + NOR LPBN 9 ± 4 −13 ± 13
Prazosin i.p. + SAL LPBN 0.7 ± 0.8 0.4 ± 4
The results are reported as means ± SEM. Number of animals = 6. Prazosin (1 mg/kg of
body weight.), noradrenaline (NOR, 40 nmol/0.2 μl), saline (SAL).
a Different from SAL + SAL.
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opioids, ATP and GABA in the LPBN modulate the inhibitory mecha-
nisms that control sodium intake (Menani et al., 1996; Menani and
Johnson, 1998; De Gobbi et al., 2001; Andrade et al., 2004; Callera
et al., 2005; De Castro e Silva et al., 2006; De Oliveira et al., 2008;
De Gobbi et al., 2009; Gasparini et al., 2009; Menezes et al., 2011).
Therefore, the signals not modiﬁed or only partially modiﬁed by α2
adrenoceptor activation in the LPBN, like the cardiovascular signals
as suggested by the present results, might bemodulated or mediated
by other neurotransmitters in the LPBN. Which neurotransmitters/
receptors mediate or modulate each signal is an important step for
future studies.
Although the activation of α2 adrenoceptors with injections of nor-
adrenaline speciﬁcally into the LPBN is the mechanism that facilitates
FURO + CAP-induced 1.8% NaCl intake (Gasparini et al., 2009 and the
present results), the central site and the mechanisms involved in the
pressor response are not clear. The injections of the same dose ofnoradrenaline into the LPBN or outside the LPBN produced similar
pressor and bradycardic responses, suggesting that thepressor response
is not dependent speciﬁcally on the action of noradrenaline into the
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Fig. 4. Changes in (A) MAP and (B) HR produced by unilateral injections of noradrenaline
(NOR, 20 nmol/0.2 μl) into the LPBN or carbachol (4 nmol/1 μl) i.c.v. In ﬂuid replete rats
pre-treated with injections of saline (SAL) or hexamethonium (HEXA, 30 mg/kg of body
weight) + vasopressin antagonist (AVPx, 10 μg/kg of body weight) injected i.v. The
results are reported as means ± SEM. n = number of animals.
Table 4
Cumulative 1.8% NaCl in FURO + CAP rats treated with bilateral injections of
noradrenaline or saline outside LPBN combined with prazosin or saline i.p.
Treatment 1.8% NaCl intake
(ml/3 h)
SAL i.p. + SAL LPBN 6.5 ± 2.3
SAL i.p. + NOR LPBN 7.8 ± 1.4
Prazosin i.p. + NOR LPBN 6.3 ± 2.2
Prazosin i.p. + SAL LPBN 3.9 ± 1.4
The results are reported as means ± SEM. Number of animals = 6. Prazosin (1 mg/kg of
body weight), noradrenaline (NOR, 40 nmol/0.2 μl), saline (SAL).
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mechanisms usually involved in the pressor responses produced by
the stimulation of central areas, like the pressor responses produced
by noradrenaline injected into the bed nucleus of the stria terminalis,
supra-optic nucleus, lateral septal area or insular cortex or the choliner-
gic activation of forebrain areas (Alves et al., 2011; Busnardo et al., 2009;
Crestani et al., 2007, 2008; Hoffman et al., 1977; Imai et al., 1989;Table 3
Changes in MAP and HR produced by bilateral injections of noradrenaline or saline
outside or into LPBN.
Treatments ΔMAP
(mm Hg)
ΔHR
(bpm)
Saline 3 ± 3 6 ± 3
NOR LPBN 41 ± 7a −81 ± 23a
NOR outside LPBN 39 ± 4a −82 ± 15a
The results are reported as means ± SEM. Number of animals = 6. Noradrenaline (NOR,
40 nmol/0.2 μl).
a Different from saline.Menani et al., 1990; Pelosi and Corrêa, 2005; Scopinho et al., 2006;
Takakura et al., 2011). Although, as expected, the double blockade
(vasopressinergic receptor and ganglionic blockade) abolished the
pressor response to central cholinergic activation, it increased the
pressor responses to injections of noradrenaline into the LPBN, rather
than reducing them, suggesting that noradrenaline injected into the
LPBN does not activate mechanisms usually involved in the pressor
responses that result from the activation of the central areas or that
noradrenaline is not acting centrally to produce pressor responses.
However, the double blockade abolished the bradycardic response to
noradrenaline injected into the LPBN and the pressor response to intra-
venous injection of vasopressin, conﬁrming that hexamethonium treat-
ment produced an effective ganglionic blockade (in this case also the
parasympathetic ganglion involved in the bradycardia) and that the
vasopressin antagonist effectively blocked peripheral vasopressin
receptors. The absence of bradycardia after the double blockade might
be the reason for the increased pressor response to noradrenaline in
this condition. Although hexamethonium combined with vasopressin
antagonist i.v. did not reduce the pressor response to noradrenaline,
prazosin i.p. abolished the pressor responses to noradrenaline injected
into the LPBN which suggests that noradrenaline injected into the
LPBNmay spread to the periphery and activate α1 adrenoceptors locat-
ed in the blood vessels to produce pressor response. The experiments
performed in anesthetized rats also showed that the injection of nor-
adrenaline into the LPBN produces pressor response and an inhibition
of sympathetic outﬂow, an effect opposite to that expected for a central
acting hypertensive agent. Therefore, the results show that noradrena-
line injected into the LPBN does not increase sympathetic activity and,
instead of this, strongly suggest that noradrenaline is probably diffusing
outside the brain to produce vasoconstriction acting directly on α1
adrenoceptors in the blood vessels.
In summary, the present results suggest that inhibitory signals from
cardiovascular receptors still affect water and NaCl intake after the
injections of noradrenaline into the LPBN. Therefore, it seems that the
activation of α2 adrenoceptors with noradrenaline injected into the
LPBN, at least in dose tested, may not completely remove the inhibitory
signals produced by the activation of the cardiovascular receptors,
particularly the signals that result from the extra activation of these
receptors produced by the increase of arterial pressure. In addition,
the pressor responses that result from the injection of noradrenaline
into the LPBN seem to depend on a direct activation of peripheral α1
adrenoceptors and not on a central action of noradrenaline.Acknowledgments
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